Your browser is no longer supported. Please, upgrade your browser.
Settings
AMGN Amgen Inc. daily Stock Chart
AMGN [NASD]
Amgen Inc.
IndexS&P 500 P/E16.82 EPS (ttm)10.26 Insider Own0.10% Shs Outstand738.86M Perf Week2.71%
Market Cap127.53B Forward P/E13.46 EPS next Y12.83 Insider Trans0.00% Shs Float738.86M Perf Month13.80%
Income7.72B PEG2.48 EPS next Q2.99 Inst Own80.20% Short Float0.80% Perf Quarter19.67%
Sales22.99B P/S5.55 EPS this Y13.10% Inst Trans-2.05% Short Ratio1.64 Perf Half Y0.36%
Book/sh40.59 P/B4.25 EPS next Y3.95% ROA10.10% Target Price183.88 Perf Year20.30%
Cash/sh51.55 P/C3.35 EPS next 5Y6.79% ROE25.90% 52W Range131.83 - 174.46 Perf YTD18.87%
Dividend4.60 P/FCF19.56 EPS past 5Y20.50% ROI13.00% 52W High-1.06% Beta1.21
Dividend %2.66% Quick Ratio3.90 Sales past 5Y8.10% Gross Margin81.90% 52W Low30.93% ATR2.81
Employees19200 Current Ratio4.10 Sales Q/Q7.70% Oper. Margin42.60% RSI (14)76.95 Volatility1.87% 1.73%
OptionableYes Debt/Eq1.16 EPS Q/Q10.50% Profit Margin33.60% Rel Volume0.72 Prev Close173.14
ShortableYes LT Debt/Eq1.01 EarningsFeb 02 AMC Payout38.70% Avg Volume3.60M Price172.61
Recom2.30 SMA205.85% SMA5011.32% SMA20010.27% Volume2,579,797 Change-0.31%
Feb-01-17Upgrade BofA/Merrill Neutral → Buy
Dec-20-16Downgrade Credit Suisse Outperform → Neutral
Dec-13-16Initiated Oppenheimer Outperform
Nov-08-16Initiated Mizuho Buy $164
Aug-26-16Initiated Gabelli & Co Hold
Jun-29-16Initiated Bernstein Mkt Perform
Feb-25-16Initiated Citigroup Neutral $165
Feb-08-16Reiterated Argus Buy $202 → $185
Jan-20-16Initiated Credit Suisse Outperform $205
Dec-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-04-15Initiated Wells Fargo Market Perform
Oct-29-15Reiterated UBS Buy $168 → $180
Sep-01-15Initiated Raymond James Mkt Perform
Jul-31-15Reiterated RBC Capital Mkts Outperform $185 → $190
Jul-31-15Reiterated Deutsche Bank Buy $192 → $195
Jul-31-15Reiterated Barclays Equal Weight $180 → $185
May-28-15Reiterated Deutsche Bank Buy $200 → $192
Apr-22-15Reiterated UBS Buy $175 → $185
Apr-22-15Reiterated RBC Capital Mkts Outperform $178 → $185
Oct-29-14Reiterated Argus Buy $140 → $185
Feb-22-17 06:21PM  Who Could Buy Bristol-Myers Squibb? at Motley Fool
03:01PM  In 'groundbreaking' deal, Harvard Pilgrim negotiates contracts to save on two pricey drugs at bizjournals.com
01:30PM  Heart-Thumping, Game-Changing Ways We're Treating Cardiovascular Disease at Motley Fool
12:21PM  Genmab and J&J's cancer drug set for blockbuster sales this year
10:37AM  Keytruda: Mercks Immuno-Oncology Blockbuster Drug
10:30AM  Amgen Gets EU Nod for Monthly Repatha Dose at Investopedia
09:30AM  The Zacks Analyst Blog Highlights: Amgen, Procter & Gamble, Bank of America, Netflix and Honda
06:43AM  Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising
Feb-21-17 04:48PM  Icahn Takes Bristol-Myers Stake With M&A In Mind; Who Could Be The Acquirer?
04:00PM  Repatha® (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery Option PR Newswire
09:34AM  Top Research Reports for Amgen, Bank of America, and Proctor & Gamble
08:54AM  Study Reveals PCSK9 Drugs Can Save Heart Disease Patients at Motley Fool
07:36AM  How Amgens Kyprolis Is Positioned in Second-Line Multiple Myeloma Segment
Feb-20-17 12:15PM  Roche Sues Amgen Over Avastin Biosimilar Drug at Investopedia
10:36AM  Repatha Represents a Solid Growth Opportunity for Amgen in 2017
09:06AM  Amgens Neutropenia Drugs May See Falling Revenues in 2017
07:36AM  Enbrel Strengthens Its Position in Rheumatology and Dermatology Segments
Feb-18-17 01:04PM  AMGEN INC Financials
Feb-17-17 03:34PM  Mylan's Proposed Biosimailar for Cancer Under Review in U.S.
10:36AM  Amgen Is Managing the Life Cycle of Its Mature Nephrology Drugs in 2017
09:12AM  Valeant's (VRX) Plaque Psoriasis Drug Approved in the U.S.
09:07AM  Parsabiv Is Expected to Boost Amgens Revenues in 2017
07:37AM  Prolia Expected to Be a Significant Growth Driver for Amgen in 2017
Feb-16-17 05:35PM  Amgen Commits to Reaching Its Long-Term Financial Targets in 2018
04:41PM  Don't Count on Valeant's New Drug to Save the Day at Motley Fool
03:36PM  Amgen Estimates Modest Revenue Performance in 2017
11:18AM  Health Care ETF Has Been Ailing
09:20AM  Why Amgen's Becoming One of My Top Dividend Stocks to Buy at Motley Fool
Feb-15-17 06:35PM  Cramer fires back at naysayers: Here's your proof that th...
05:59PM  Proof the rally is real
05:19PM  Biotech boom?
12:22PM  Amgen Applies for Leukemia Drug Label Expansion at Investopedia
09:48AM  Want to Get In on Biotech? Check Out These 3 Stocks at Motley Fool
08:31AM  Amgen Looking to Broaden Leukemia Drug Blincyto's Label
Feb-14-17 05:07PM  AMGEN INC Files SEC form 10-K, Annual Report
09:00AM  Amgen Submits Supplemental Biologics License Application For BLINCYTO® (Blinatumomab) In Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia PR Newswire
Feb-13-17 05:30PM  Daniel Loeb Picks Up Rate-Sensitive Financials, Drops Pharma
Feb-10-17 09:55AM  Major Biotechs Scare Off Loads of Short Sellers
08:38AM  Biotech ETFs Powered by Q4 Earnings
Feb-09-17 04:56PM  Regeneron Defies Light Q4 Sales, Eylea Outlook On Amgen-Rivaling LDL Win
02:01PM  Regeneron: Whiplash! at Barrons.com
01:11PM  Regeneron Pharmaceuticals Inc (REGN) and Sanofi SA (ADR) (SNY) Obtain Suspension of Injunction for Cholesterol Drug Sales at Insider Monkey
11:09AM  Regeneron (REGN) Misses on Q4 Earnings & Sales, View Bleak
10:56AM  Judge Lifts Ban on Amgen Cholesterol Drug Rival at Investopedia
09:05AM  Acorda, Amgen and Regeneron Lead Premarket Biotech Movers
08:31AM  Regeneron forecasts 2017 U.S. Eylea sales growth below estimates
08:17AM  A Heart-Stopping Patent Injunction Stay For Sanofi at Forbes
Feb-08-17 07:02PM  [$$] Appeals Court Allows Sanofi, Regeneron to Continue Selling Cholesterol Drug at The Wall Street Journal
05:45PM  Gilead tanks on weak forecast
05:33PM  Regeneron, Sanofi Temporarily Stave Off Ban Of Amgen-Rivaling LDL-Buster
04:49PM  Federal appeals court decision will keep Regeneron/Sanofi drug at center of patent dispute on market, for now at MarketWatch
04:39PM  Judge: Regeneron can keep selling cholesterol drug
04:14PM  Regeneron (REGN) Q4 Earnings: Will the Stock Disappoint?
12:48PM  FDA Approves Amgen, Inc. (AMGN) Drug For Treating Secondary Hyperparathyroidism at Insider Monkey
12:03PM  Why Coherus Biosciences Is Falling Today at Motley Fool
11:39AM  Coherus Biosciences Inc (CHRS) Could Be A Discount Entry On The Pullback at Insider Monkey
10:48AM  Amgen Gets FDA Approval for Kidney Drug Parsabiv at Investopedia
09:02AM  Amgen's Secondary Hyperparathyroidism Drug Approved in U.S.
08:23AM  Better Buy: Amgen Inc. vs. Celgene at Motley Fool
06:45AM  Biotech Stock Roundup: Amgen, Gilead Report 4Q Results, ARIAD Seeks EU Nod for Brigatinib
03:25AM  Drugmaker Sanofi sees weak 2017 earnings, not in hurry for M&A
Feb-07-17 07:05PM  Cramer: The right time to buy more oil stocks at CNBC
06:20PM  U.S. FDA approves Amgen drug for secondary hyperparathyroidism Reuters
06:13PM  FDA Approves Amgen's Parsabiv (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis PR Newswire
02:08PM  Amgen, Inc. :AMGN-US: Earnings Analysis: 2016 By the Numbers : February 7, 2017
12:50PM  Whats Next For Esperion Therapeutics Inc (ESPR)? at Insider Monkey
09:06AM  Drug Stock Q4 Earnings to Watch on Feb 8: AGN, GSK & More
Feb-06-17 12:40PM  Priced like an automaker, sputtering Gilead shares lure value bets
10:44AM  Amgen, Inc. :AMGN-US: Earnings Analysis: Q4, 2016 By the Numbers : February 6, 2017
10:10AM  Company News for February 06, 2017
08:02AM  Amgen Stock Buoyed By Positive Repatha Study at Investopedia
12:42AM  [$$] Good News for Amgen Is Good News for Biotech at The Wall Street Journal
Feb-05-17 07:23AM  Trump's Plan to Lower Drug Costs Is a Fairy Tale at Motley Fool
Feb-03-17 06:11PM  Trading Friday's rally: 6 plays at CNBC
05:49PM  Why Morgan Stanley, Amgen, and Tableau Software Jumped Today at Motley Fool
05:05PM  Banks lead stock surge as investors hope for regulation cuts
04:32PM  Why The Medicines Company Rocketed Higher Today at Motley Fool
04:24PM  Amgen's LDL-Buster Boosts The Medicines Co., But Regeneron Slides
04:15PM  BetterInvesting Magazine Releases April Stock To Study And Undervalued Stock Choices For Investors' Informational And Educational Use PR Newswire
04:04PM  Amgen Announces Appointment of Charles M. Holley Jr. to Board of Directors PR Newswire
03:38PM  Why Esperion Therapeutics, Inc. Is Soaring Today at Motley Fool
03:15PM  Amgen: Who Says Biotech's Dead? at Barrons.com
12:43PM  [$$] Good News for Amgen Is Good News for Biotech at The Wall Street Journal
12:16PM  Repatha Will Test the New Drug Pricing Reality at Bloomberg
11:08AM  Amgen Q4 Earnings Beat Street Forecasts at Investopedia
10:47AM  Dow Retakes 20,000 As Visa, Goldman, Rally; Amazon Sinks, But Amgen Soars
10:25AM  Stocks Open Higher As Payrolls Surge, Dow Passes 20,000 Again
08:38AM  Are Options Traders Betting on a Big Move in Amgen (AMGN) Stock?
08:01AM  Early movers: AMZN, CLX, AN, HSY, F, AMGN & more at CNBC
06:59AM  Amgen (AMGN) Q4 Earnings Top; Repatha Positive in CV Study
04:40AM  Edited Transcript of AMGN earnings conference call or presentation 2-Feb-17 10:00pm GMT
Feb-02-17 07:20PM  Fast Money traders discuss how to trade Amgen and Amazon earnings at CNBC
06:50PM  [$$] Amgen Sees Positive Results in Repatha Study at The Wall Street Journal
06:15PM  Amgen fourth quarter profit tops Street view, cholesterol news lifts shares
06:14PM  Amgen 4th-qtr profit tops Street view, cholesterol news lifts shares
05:49PM  Amgen CEO: Will work with Trump to lower drug prices
05:32PM  Biogen: What Now? at Barrons.com
05:00PM  How to trade Amgen/Amazon earnings: 5 trades
05:00PM  Amgen Inc Earnings Call scheduled for 5:00 pm ET today
04:58PM  Amgen Crushes Q4 Views, But Sees Light 2017 Sales; Repatha Tops CV Study
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for the prevention of skeletal-related events; Repatha to treat coronary artery diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Erenumab for the prevention of chronic migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; AMJEVITA to treat psoriatic arthritis and polyarticular juvenile idiopathic arthritis, as well as ankylosing spondylitis and moderate-to-severe rheumatoid arthritis; ABP 215 for biosimilar candidates; and ABP 980 to treat human epidermal growth factor receptor 2-positive early breast cancer. The company's other marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products for use to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
de Carbonnel FrancoisDirectorSep 09Option Exercise71.645,000358,20021,171Sep 13 06:21 PM
Such Annette LouiseVP, Finance and CAOAug 02Sale174.593,000523,7587,183Aug 03 08:14 PM
Balachandran MadhavanEVP, OperationsMay 04Sale154.1230,0004,623,62455,996May 05 08:16 PM
BALTIMORE DAVIDDirectorApr 29Sale157.213,312520,68432,350May 03 07:12 PM
BALTIMORE DAVIDDirectorMar 30Option Exercise50.445,000252,20037,350Mar 31 06:01 PM
HERRINGER FRANK CDirectorMar 14Option Exercise50.445,000252,20030,608Mar 16 06:48 PM
COFFMAN VANCE DDirectorMar 09Option Exercise50.445,000252,20043,447Mar 10 06:55 PM
Bradway Robert AChairman, CEO and PresidentMar 02Option Exercise50.4484,0004,236,960447,102Mar 04 06:07 PM
Bradway Robert AChairman, CEO and PresidentMar 02Sale146.4820,0002,929,566383,102Mar 04 06:07 PM